Safeguarding Patients in Clinical Trials with High Mortality Rates
- 15 July 2001
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 164 (2) , 190-192
- https://doi.org/10.1164/ajrccm.164.2.2011028
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Severe Traumatic Hemorrhagic ShockA Randomized Controlled Efficacy TrialJAMA, 1999
- Growth Hormone Therapy in Critically Ill PatientsNew England Journal of Medicine, 1999
- Increased Mortality Associated with Growth Hormone Treatment in Critically Ill AdultsNew England Journal of Medicine, 1999
- Critical-care studies: redefining the rulesThe Lancet, 1998
- DOSE-DEPENDENT EFFECT OF DIASPIRIN CROSS-LINKED HEMOGLOBIN ON REGIONAL BLOOD CIRCULATION OF SEVERELY HEMORRHAGED RATSShock, 1998
- Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb[trademark symbol]) as a vasopressor in critically ill patientsCritical Care Medicine, 1997
- Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solutionCritical Care Medicine, 1996
- Time‐dependent enhancement or inhibition of endotoxin‐induced vascular injury in rat intestine by nitric oxide synthase inhibitorsBritish Journal of Pharmacology, 1994
- Protective and pathological roles of nitric oxide in endotoxin shockCardiovascular Research, 1992
- Inhibition of nitric oxide synthesis in septic shock: how much is beneficial?The Lancet, 1991